Mesenchymal stem cells as a potential therapy for COVID-19

Area of Science:

• Immunology
• Regenerative Medicine
• Pulmonology

Background:

• The COVID-19 pandemic presents a significant global health challenge, with severe cases often exhibiting pathology consistent with acute lung injury (ALI) or acute respiratory distress syndrome (ARDS).
• Current treatment options for severe COVID-19, particularly those targeting the associated lung damage, remain limited.
• Mesenchymal stem cells (MSCs) have demonstrated immunomodulatory properties and therapeutic potential in preclinical and clinical studies for various causes of ALI/ARDS.

Discussion:

• This commentary reviews existing clinical trial data on MSCs for ALI/ARDS.
• It explores the potential mechanisms by which MSCs could mitigate the lung inflammation and damage characteristic of severe COVID-19.
• The application of MSCs is considered a viable therapeutic strategy for managing critical COVID-19 patients.

Key Insights:

• Severe COVID-19 frequently involves lung pathology similar to ALI/ARDS, characterized by inflammation and edema.
• Mesenchymal stem cells (MSCs) possess the ability to modulate immune responses, offering a potential therapeutic avenue.
• Previous research indicates MSCs are effective in treating ALI/ARDS from diverse etiologies.

Outlook:

• Further clinical investigation into MSC-based therapies for severe COVID-19 is warranted.
• MSCs could represent a novel and hopeful treatment option for patients with critical respiratory complications.
• Successful MSC application may improve outcomes for individuals suffering from COVID-19-induced lung injury.